[1]World Health Organization. Global tuberculosis report.Geneva:World Health Organization, 2012.[2]World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis-emergency update. Geneva:World Health Organization, 2008.[3]Raviglione MC, Dye C, Schmidt S, et al. Assessment of worldwide tuberculosis control. WHO global surveillance and monitoring project. Lancet, 1997,350(9087):624-629.[4]Dye C, Espinal MA, Watt CJ, et al. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis,2002,185(8):1197-1202.[5]Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med, 2007, 4(1):e50.[6]Lonnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet, 2010, 375(9728):1814-1829.[7]World Health Organization. The Beijing “call for action” on tuberculosis control and patient care: together addressing the global M/XDR-TB epidemic[R/OL]. Geneva: World Health Organization,2009(2009-04-01) [2013-07-24]. http://www.who.int/tb_beijingmeeting/media/en_call_for_action.pdf.[8]中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年).北京:人民卫生出版社, 2010.[9]Dye C, Williams BG, Espinal MA, et al. Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis.Science,2002,295(5562):2042-2046.[10]Crofton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis. WHO/TB/96.2.10. Geneva:World Health Organization, 1996.[11]张立兴,阚冠卿. 北京结核病控制规程改革15年. 中华结核和呼吸杂志,1995,18(6):337-339.[12]杜雨华,苏汝钊,周惠贤,等. 116例耐多药肺结核治疗转归情况影响因素分析.中国防痨杂志, 2012,34(1):21-24.[13]Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med, 2012, 9(8): e1001300.[14]谢艳光,房宏霞,闫兴录,等. 黑龙江省耐多药与非耐多药肺结核患者在DOTS策略下远期治疗效果分析. 中国防痨杂志, 2012,34(2):73-78. |